Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Allarity Therapeutics, Inc.
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
May 26, 2026
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
May 25, 2026
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 24, 2026
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
May 23, 2026
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
May 19, 2026
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
February 3, 2026